GALECTIN Earnings Monday, November 16, 2026 +0.80 Positive

Galectin reports 3Q 2026 financial results and provides business update

Galectin Therapeutics filed its registrational Phase 3 protocol for belapectin in MASH cirrhosis and presented positive data at AASLD.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed